GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Related
Building long-term value through commercial property and urban regeneration
Central Business Centres plc's approach to property investment goes beyond acquisition and ownership.
‘As a country we can’t agree on what a start-up actually is’ – Malta Startup Space community leader
'We tend to apply SME-related metrics to startups in areas like funding,' he said.
BNF Bank approves nomination of Izzat Nuseibeh as Chairperson
During the meeting the bank also re-confirmed Sheikh Jassim Feisal Q.F. Al-Thani as Deputy Chairman.
Ian Fenech Conti appointed Chief Technology Officer of Loqus Holdings
He has been with the company for over 15 years where he served as the Head of Research and Development ...
